Accepted for/Published in: JMIR Medical Informatics
Date Submitted: Jun 18, 2020
Date Accepted: Sep 21, 2020
Date Submitted to PubMed: Oct 10, 2020
Detect Severe COVID-19 Infection: A Signature of Chest CT and Laboratory Measurement
ABSTRACT
Background:
Most of mortality of COVID-19 were from severe patients. Effective treatment of these severe cases remains a challenge due to a lack of early detection.
Objective:
Herein, we presented a prediction model, combining the radiological outcome with the clinical biochemical indexes, to identify the severe cases.
Methods:
A total set of 27 severe and 151 non-severe clinical and CT (computerized tomography) records from 46 COVID-19 patients (10 severe, 36 non-severe) was collected for building the model. Using a recent published CNN (convolutional neural network), we managed to extract features from CT images. A machine learning model which combines these features with clinical laboratory results also was trained.
Results:
Herein, we presented a prediction model, combining the radiological outcome with the clinical biochemical indexes, to identify the severe cases. The prediction model yields a cross-validated AUROC score of 0.93 and F1 score of 0.89, which improved 6% and 15%, respectively, from the models with laboratory tests features only. In addition, we also developed a statistical model for forecasting severity based on patients’ laboratory tests results before turning severe cases, with an AUROC score of 0.81.
Conclusions:
To our knowledge, this is the first report to predict COVID-19 patient’s severity progression, as well as severity forecasting, through a combination analysis of laboratory tests and CT images.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.